Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 19/20 | 0.54 |
| ▸ | HSD11B2 | P80365 | 9/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL233640 | 0.91 | HSD11B1 (0.60) | HSD11B1HSD11B2LMNATSHRALOX12 | |
| SCHEMBL15899880 | 0.85 | HSD11B1 (0.49) | HSD11B1HSD11B2LMNATSHRALOX12 | |
| SCHEMBL5243064 | 0.80 | HSD11B1 (0.56) | HSD11B1HSD11B2 | |
| SCHEMBL230443 | 0.79 | LMNA (0.44) | HSD11B1HSD11B2LMNATSHRALOX12 | |
| SCHEMBL2824031 | 0.78 | HSD11B1 (0.49) | HSD11B1HSD11B2LMNATSHRALOX12 | |
| SCHEMBL2824032 | 0.78 | HSD11B1 (0.49) | HSD11B1HSD11B2LMNATSHRALOX12 | |
| SCHEMBL2357720 | 0.78 | LMNA (0.51) | HSD11B1HSD11B2LMNATSHRALOX12 | |
| SCHEMBL2835294 | 0.78 | HSD11B1 (0.50) | HSD11B1HSD11B2 | |
| SCHEMBL230588 | 0.77 | HSD11B1 (0.53) | HSD11B1HSD11B2 | |
| SCHEMBL230433 | 0.76 | HSD11B1 (0.63) | HSD11B1HSD11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120004206-A1 | INHIBITORS OF THE 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ENZYME | ABBVIE INC. | 2012-01-05 | — | — | US | disclosed |
| EP-2345640-A1 | Adamantyl- acetamide derivatives as inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme | Abbott Laboratories (US) | 2011-07-20 | — | — | EP | disclosed |
| US-7880001-B2 | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme | ABBOTT LABORATORIES (US) | 2011-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120004206-A1 | INHIBITORS OF THE 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ENZYME | HSD11B1, HSD17B1, HSD11B2 | HSD11B1 1/4885HSD11B2 3/4885LMNA 4105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.